Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Experts say the ACR/AAHKS 2022 guidelines for patients undergoing total hip replacement or total knee replacement have several limitations that limit the effectiveness of their recommendations.
Read Full NewsA study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.
A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.
Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.
1.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
2.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
3.
Virtual Reality Travel Reduces Cancer Pain.
4.
Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations
5.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
1.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
2.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
3.
New Research on Craniopharyngioma
4.
A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era
5.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
2.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
3.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge